National University Hospital Medical Centre
Singapore 119082
3 studies enrolling now · 9 studies all time
What they study most
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC, Advanced Non-small Cell Lung Cancer, Advanced Solid Tumors, Advanced/Metastatic Colorectal Adenocarcinoma, Chronic Kidney Disease, EGFR Mutation, HER2 Mutation, MTAP-deleted Solid Tumors, Neovascular Age-Related Macular Degeneration, Non-diabetic Chronic Kidney Disease
Studies at this site
- A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation — Recruiting now
- First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) — Recruiting now
- A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors — Recruiting now
- A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors — Running, not enrolling
- A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease — Completed
- A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease — Completed
- Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye — Completed
- A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults — Stopped early
- A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations — Completed